FL-ZYCUS
20.5.2024 15:01:27 CEST | Business Wire | Press release
Zycus, the pioneer in Generative AI-powered Source-to-Pay solutions, ignited a wave of innovation at its annual procurement conference, Horizon 2024. The event showcased a groundbreaking suite of GenAI advancements designed to elevate automation, intelligence, and efficiency throughout the Source-to-Pay (S2P) process.
Zycus Revolutionizes Procurement with Merlin
Zycus introduced a two-pronged approach to GenAI-powered procurement:
- Merlin Assist Chatbot: Integrated with Microsoft Teams, this AI assistant acts as the "front door" to procurement, allowing users to ask questions, extract contract details, generate summaries, develop strategies, and streamline workflows—all within the familiar Teams environment. As we say at Zycus, AI is the new UI.
- Merlin GenAI Power Apps: Delivered through AppXtend, these applications unlock 10x efficiency and effectiveness, addressing critical tasks such as streamlining approvals, automating contract risk management, simplifying sourcing, enhancing Accounts Payable, automating project management, facilitating supplier risk management, and validating reports with Insight Studio.
"Zycus' Merlin GenAI addresses critical pain points across the S2P process, surpassing basic automation like invoice processing or user assignment," said the Head of Indirect Procurement of a Global 500 company at Horizon.
Aatish Dedhia, Founder & CEO of Zycus, highlighted, "With over 20 years of AI-driven innovation including five years with the Merlin AI platform, Zycus has built deep, well-managed datasets, ensuring effective GenAI model training and a nuanced understanding of customer needs. Our AppXtend API framework enables rapid development, deployment, and deep integration of GenAI across S2P processes.”
Industry Validation: Microsoft Recognizes Zycus Leadership
"AI will transform the way individuals, teams, and organizations work," said Samik Roy, Executive Director, Corporate, Medium and Small Businesses, Microsoft India. "Zycus has integrated Azure OpenAI to infuse AI into its daily operations. The quantitative impact is very encouraging. From personalized experiences to streamlined workflows, AI will start becoming the cornerstone of Zycus's success."
Zycus Horizon: A Springboard for GenAI Leadership
Horizon 2024 served as a powerful platform for Zycus to demonstrate its leadership in GenAI-powered procurement solutions, empowering businesses with significant efficiency gains, agility, cost savings, and a competitive advantage.
About Zycus:
Zycus is the leader in Source-to-Pay (S2P) solutions, pioneering the world's first Generative AI powered platform that helps procurement achieve 10X speed and efficiency. It has been a trusted partner of choice for large global enterprises and is consistently recognized by leading analysts like Gartner and Forrester.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240520570248/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom